STRADA Gene Polyhydramnios Megalencephaly and Symptomatic Epilepsy NGS Genetic DNA Test
Comprehensive Genetic Testing for Neurodevelopmental Disorders
The STRADA Gene Polyhydramnios Megalencephaly and Symptomatic Epilepsy NGS Genetic DNA Test represents a breakthrough in pediatric genetic diagnostics. This advanced test specifically targets mutations in the STRADA (also known as LYK5) gene, which plays a critical role in the mTOR signaling pathway – a fundamental regulator of cell growth, proliferation, and metabolism. When mutations occur in this gene, they can lead to a rare but serious neurodevelopmental condition characterized by distinctive clinical features.
What Does This Test Detect?
Our comprehensive NGS-based genetic test precisely identifies pathogenic variants in the STRADA gene that are responsible for:
- Polyhydramnios during pregnancy (excessive amniotic fluid accumulation)
- Megalencephaly (abnormally enlarged brain structure)
- Symptomatic epilepsy and seizure disorders
- Developmental delays and intellectual disabilities
- Autism spectrum features
- Distinctive facial characteristics
Advanced NGS Technology
Utilizing state-of-the-art Next-Generation Sequencing technology, our test provides comprehensive coverage of the entire STRADA gene with exceptional accuracy exceeding 99%. This methodology enables detection of single nucleotide variants, small insertions/deletions, and copy number variations that traditional testing methods might miss.
Who Should Consider This Test?
This genetic test is recommended for individuals presenting with the following clinical indications:
- Infants and children with unexplained megalencephaly
- Patients with symptomatic epilepsy resistant to conventional treatments
- Individuals with developmental delays and intellectual disabilities of unknown origin
- Patients with a family history of STRADA-related disorders
- Prenatal cases with polyhydramnios and abnormal ultrasound findings
- Children exhibiting autism spectrum behaviors with associated neurological symptoms
Clinical Symptoms That Warrant Testing
- Persistent seizures beginning in infancy or early childhood
- Macrocephaly (large head circumference) disproportionate to body size
- Motor delays and coordination difficulties
- Speech and language development concerns
- Behavioral challenges including autism spectrum features
- Distinct facial features such as frontal bossing and hypertelorism
Benefits of STRADA Gene Testing
Undergoing this comprehensive genetic analysis provides numerous advantages for patients and families:
- Accurate Diagnosis: Provides definitive identification of the underlying genetic cause
- Personalized Treatment: Enables targeted therapeutic approaches based on genetic findings
- Genetic Counseling: Supports informed family planning decisions
- Prognostic Information: Helps predict disease progression and potential complications
- Early Intervention: Facilitates timely implementation of appropriate therapies
- Research Contribution: Advances understanding of rare genetic disorders
Understanding Your Test Results
Our comprehensive genetic report provides clear, actionable information:
Positive Result Interpretation
A positive result indicates the presence of pathogenic mutations in the STRADA gene. This confirms the genetic diagnosis and provides essential information for:
- Developing personalized treatment strategies
- Implementing appropriate seizure management protocols
- Planning developmental interventions and educational support
- Discussing recurrence risks with genetic counselors
Negative Result Interpretation
A negative result suggests that no pathogenic variants were detected in the STRADA gene. However, this doesn’t completely rule out the possibility of a genetic disorder, as mutations in other genes or regulatory regions might be responsible for the clinical presentation.
Variant of Uncertain Significance (VUS)
In some cases, the test may identify genetic changes whose clinical significance is currently unknown. Our genetic counseling team provides comprehensive guidance on how to interpret these findings and recommends appropriate follow-up testing when necessary.
Test Pricing and Details
| Test Component | Details |
|---|---|
| Test Name | STRADA Gene Polyhydramnios Megalencephaly and Symptomatic Epilepsy NGS Genetic DNA Test |
| Discount Price | $500 USD |
| Regular Price | $700 USD |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type | Blood, Extracted DNA, or One Drop Blood on FTA Card |
| Methodology | Next-Generation Sequencing (NGS) |
Pre-Test Requirements
To ensure optimal testing outcomes, we require:
- Complete clinical history of the patient
- Genetic counseling session to discuss testing implications
- Development of a detailed pedigree chart documenting family medical history
- Informed consent for genetic testing
Nationwide Testing Availability
We proudly serve patients across the United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more. Our network of certified genetic counselors and medical professionals ensures consistent, high-quality care regardless of location.
Take the Next Step Toward Genetic Clarity
Don’t let uncertainty about your child’s neurological symptoms continue. Our STRADA gene testing provides the answers you need to make informed medical decisions and develop effective treatment strategies. With our discounted price of only $500 USD (regularly $700), comprehensive genetic analysis is more accessible than ever.
Call our genetic specialists today at +1(267) 388-9828 to schedule your consultation and testing appointment. Our team is ready to provide the expert guidance and support you need throughout this important diagnostic journey.
Take control of your genetic health and unlock the power of precision medicine with our advanced STRADA gene testing services.
